Clinical Trial Update: Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo [Phase 3]

View source ↗

Summary

A Phase 3 trial sponsored by AstraZeneca evaluated relapse prevention in stable chronic schizophrenia patients, comparing Seroquel (quetiapine) to placebo; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEROQUEL (QUETIAPINE)

Snippet

Sponsor: AstraZeneca | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED